Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Kazia Therapeutics ( (KZIA) ).
On April 10, 2026, Kazia Therapeutics entered a license and commercialization agreement with QIMR Berghofer Medical Research Institute to acquire exclusive global rights to a first-in-class SETDB1-targeted epigenetic drug development platform. The deal includes an upfront payment of about $1.39 million and a tiered revenue-sharing structure, adding lead candidate MSETC and an AI-integrated discovery engine to Kazia’s portfolio.
The SETDB1 platform targets a key epigenetic regulator of tumor immune evasion, aiming to restore immune signaling and overcome resistance to immunotherapies, including checkpoint inhibitors. Kazia plans to advance the SETDB1 program, now in preclinical development, in parallel with its nuclear PD-L1 degrader, expecting to bring both to IND readiness in roughly 18 months at a combined cost of about $6 million, strengthening its differentiated, multi-layered oncology platform and enhancing partnering potential in a $15–20 billion epigenetic therapeutics market.
The most recent analyst rating on (KZIA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with negative equity). Technicals are a notable offset with strong momentum above major moving averages, but overbought signals add near-term risk; valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a Sydney-based, clinical-stage oncology-focused drug development company listed on Nasdaq. Its lead asset is paxalisib, a brain-penetrant PI3K/Akt/mTOR inhibitor in multiple cancer trials, alongside pipeline assets EVT801 and NDL2 targeting VEGFR3 and nuclear PD-L1 to address treatment resistance in aggressive tumors.
The company operates in the oncology therapeutics market, targeting solid and brain tumors with a focus on treatment-refractory disease and immunotherapy resistance. With regulatory designations including Orphan Drug and Fast Track for paxalisib in several indications, Kazia is positioning itself within a large and growing global market for next-generation, mechanism-driven cancer therapies.
Average Trading Volume: 190,977
Technical Sentiment Signal: Hold
Current Market Cap: $99.98M
For an in-depth examination of KZIA stock, go to TipRanks’ Overview page.